Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Grants RNAi Patent License to Reagent Supplier Eurogentec

NEW YORK, July 12 (GenomeWeb News) - RNA interference company Alnylam Pharmaceuticals has given a non-exclusive license to patents in its Kreutzer-Limmer IP portfolio to Eurogentec, a life science reagent supplier.


The license enables Eurogentec to use the IP for research products and services, Alnylam said. The patent family covers short interfering RNAs and their use to mediate RNAi in mammalian cells.

The agreement brings to 11 the number of companies to which Alnylam has licensed the patent family. Six of these firms are research product suppliers, the company said.

The Scan

Review of Approval Process

Stat News reports the Department for Health and Human Services' Office of the Inspector General is to investigate FDA's approval of Biogen's Alzheimer's disease drug.

Not Quite Right

A new analysis has found hundreds of studies with incorrect nucleotide sequences reported in their methods, according to Nature News.

CRISPR and mRNA Together

Time magazine reports on the use of mRNA to deliver CRISPR machinery.

Nature Papers Present Smartphone Platform for DNA Diagnosis of Malaria, Mouse Lines for Epigenomic Editing

In Nature this week: a low-cost tool to detect infectious diseases like malaria, and more.